Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a common gout pill shield hearts after stents?

NCT ID NCT06472908

Disease control Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 03, 2026 · Last updated Sep 04, 2026 · Updated 1 time

Summary

This trial tests whether taking a daily low dose of colchicine, an anti-inflammatory drug, can reduce the risk of heart attacks, strokes, and other heart problems in Chinese patients who have had a stent placed for coronary heart disease. Researchers will compare two different doses of colchicine against a placebo in about 8,800 patients. The goal is to find out if this treatment is both effective and safe for this population.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
colchicine
What this could lead to
If it works, this could establish colchicine as a standard anti-inflammatory treatment to prevent future heart attacks and strokes in Chinese patients after stent placement.
What could go wrong
The trial is large but still experimental in China. Colchicine may cause side effects, and the lower dose might not work as well, or the higher dose might be less safe.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 8,862 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2024

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * (1) Capable and willing to provide informed consent; * (2) Age ≥18 and ≤80 years old, regardless of sex; * (3) Hospitalized patients with CHD requiring PCI; * (4) Completion of all planned PCI during hospitalization; * (5) Standardized treatment of coronary artery disease according to national guidelines. Exclusion Criteria: * (1) Known allergy to colchicine; * (2) Colchicine taken within 10 days prior to randomization group; * (3) Patients currently in cardiogenic shock or hemodynamically unstable; * (4) Patients with known inflammatory bowel disease or chronic diarrhea; * (5) Abnormal liver function (ALT\> 3 times the upper limit of normal); * (6) Abnormal renal function (eGFR\<30mL/min/1.73m2); * (7) Active malignant tumors reported in past medical history; * (8) Existing or planned treatment with other anti-inflammatory or immunosuppressive drugs; * (9) Pregnant women, lactating women or women of childbearing age who did not use effective contraceptives; * (10) Any other circumstances in which the investigator judges that the patient is not suitable to participate in the clinical trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colchicine are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colchicine poisoning coronary artery disorder Coronary Disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Colchicine Coronary heart disease Percutaneous coronary intervention

Contacts and locations

Locations

  • China Resources and WISCO General Hospital

    Wuhan, Hubei, China

  • Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, 430022, China

  • Dongfeng General Hospital, Hubei University of Medicine

    Shiyan, Hubei, China

  • Fifth Hospital in Wuhan

    Wuhan, Hubei, China

  • Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College

    Beijing, Beijing Municipality, China

  • Fuwai Huazhong Cardiovascular Hospital

    Zhengzhou, Henan, China

  • Huangshi Central Hospital

    Huangshi, Hubei, China

  • Jingzhou Central Hospital

    Jingzhou, Hubei, China

  • Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, China

  • Shandong Provincial Hospital

    Jinan, Shandong, China

  • Shanghai Sixth People's Hospital

    Shanghai, Shanghai Municipality, China

  • Shanxi Cardiovascular Disease Hospital

    Taiyuan, Shanxi, China

  • Shiyan Renmin Hospital

    Shiyan, Hubei, China

  • Songjiang Hospital Affiliated with Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, China

  • Suizhou Central Hospital

    Suizhou, Hubei, China

  • Taihe hospital

    Shiyan, Hubei, China

  • The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture

    Enshi, Hubei, China

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China

  • The First Affiliated Hospital of Dalian Medical University

    Dalian, Liaoning, China

  • The First Affiliated Hospital of Harbin Medical University

    Harbin, Harbin, China

  • The First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, China

  • The General Hospital of Northern Theater Command of the Chinese People's Liberation Army

    Shenyang, Liaoning, China

  • The Second Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China

  • The Second Hospital & Clinical Medical School, Lanzhou University

    Lanzhou, Gansu, China

  • Wuhan Asia Heart Hospital

    Wuhan, Hubei, China

  • Wuhan Central Hospital

    Wuhan, Hubei, China

  • Wuhan First Hospital

    Wuhan, Hubei, China

  • Wuhan Fourth Hospital

    Wuhan, Hubei, China

  • Wuhan Puren Hospital

    Wuhan, Hubei, China

  • Wuhan Sixth Hospital, Affiliated Hospital of Jianghan University

    Wuhan, Hubei, China

  • Wuhan Third Hospital

    Wuhan, Hubei, China

  • Wuhan Wuchang Hospital

    Wuhan, Hubei, China

  • Xiangyang Central Hospital

    Xiangyang, Hubei, China

  • Xiangyang First People's Hospital

    Xiangyang, Hubei, China

  • Xianning Central Hospital

    Xianning, Hubei, China

  • Yichang Central People's Hospital

    Yichang, Hubei, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.